AstraZeneca Reports real-world evidence Data for Pertuzumab in Chronic kidney disease

AstraZeneca today announced real-world evidence results for pertuzumab in patients with chronic kidney disease. The study demonstrated that pertuzumab significantly improves overall survival compared to standard of care or placebo. These results provide important insights into the treatment of chronic kidney disease and support the continued development of pertuzumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.